Search

everythinglearnresearchcommunity

for

Search:↓

Dopaminergic therapy in Parkinson's disease patients is linked to increased hair loss.

A woman with Parkinson's disease experienced hair loss from the Parkinson's medication pramipexole, which improved after stopping the drug.

Testosterone is important for men's sexual function, may help some women's sexual desire, while other hormones and neurotransmitters also play complex roles in sexual behavior.

Testosterone is key for male sexual function, and treating hormone imbalances can improve sexual issues.

Dopamine stops hair growth and pigment production in human scalp hair follicles.

Prolactin slows down hair growth in mice.

Goat reproductive activity and coat growth are affected by light and temperature, with temperature altering prolactin levels and hair growth, but not melatonin or estrus onset.

Prolactin may affect hair growth differently based on gender and scalp area.

Prolactin levels and gene polymorphism are not linked to vitiligo severity but are related to BMI.

A small number of premenopausal female blood donors had high prolactin levels, often due to stress, and retesting is recommended to prevent misdiagnosis.

Women with a certain type of hair loss had lower levels of a hormone called prolactin compared to healthy women.

Neurosteroids affect prolactin levels in sheep differently depending on stress and pregnancy conditions.

Amenorrhea is relatively rare and initial testing should check FSH, TSH, and prolactin levels.

Hormonal imbalances, often indicating conditions like PCOS, are common in women with hard-to-treat acne, and a treatment approach addressing these imbalances may be needed.

Some drugs can cause serious side effects like heart issues and nervous system problems, but certain drugs for Parkinson's and overactive bladder may be safer, though they still have some common side effects.

Hormones during pregnancy and lactation keep skin stem cells inactive, preventing hair growth.

The document concludes that identifying the cause of amenorrhea is crucial for proper treatment.

Amenorrhea is when a woman doesn't have periods, with primary amenorrhea starting by age 15 or within five years of breast development, and secondary amenorrhea when periods stop for three months. It affects 3-4% of women not pregnant, breastfeeding, or in menopause, mainly due to polycystic ovary syndrome, hypothalamic amenorrhea, hyperprolactinemia, and ovarian failure.

Amenorrhea, or the absence of periods, should be evaluated by age 15 or within five years of early breast development, and is most commonly caused by conditions like polycystic ovary syndrome and hypothalamic amenorrhea.

Finasteride may decrease semen quality but not harm sperm production, and stopping the drug can improve semen quality; hyperprolactinemia can cause infertility but is treatable with medication.

The document concludes that breast pain should be managed with personalized treatment, starting with non-drug methods and progressing to medication if necessary, while considering side effects and patient needs.

Seborrhea in Parkinson's disease may be linked to hormones, not autonomic impairment.

A teenage girl's excessive hair growth was caused by a medication for mania, but improved after stopping the medication.

Transdermal testosterone can improve sexual desire in postmenopausal women but lacks long-term safety data and is not FDA-approved for this use.

Cabergoline is more effective and has fewer side effects than bromocriptine for treating women with hyperprolactinemic amenorrhea.

Higher doses of oestradiol implants improve bone density in postmenopausal women.

Long-term use of oral contraceptives, especially starting before age 20, may increase the risk of early-onset breast cancer.

The report recommends personalized treatment for women's sexual dysfunctions and more research on effective therapies.

Some patients taking finasteride or dutasteride may have ongoing sexual problems and depression even after stopping the medication.